XmAb 5592
Names
[ CAS No. ]:
1221901-33-2
[ Name ]:
XmAb 5592
Biological Activity
[Description]:
XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP)[1].
[Related Catalog]:
[In Vitro]
XmAb 5592 (0-1000 ng/mL) 增强对多发性骨髓瘤 (MM) 细胞的抗体依赖细胞细胞毒性 (ADCC) 和抗体依赖细胞吞噬作用 (ADCP)。与 IgG1 类似物相比，XmAb 5592 在 5-27 ng/mL 范围内显著增加所有细胞系 ADCC，还可增强巨噬细胞的抗体依赖性细胞吞噬作用 (ADCP)[1]。 XmAb 5592 (0-10000 ng/mL) 通过脱颗粒 NK 细胞诱导强烈的 MM 细胞裂解，即使存在骨髓基质细胞 (BMSCs)[1]。
[In Vivo]
XmAb 5592 (0.3-9 mg/kg；i.p.；每周 2 次，每次 7 剂；RPMI8226 荷瘤 SCID 小鼠) 通过 FcγR 依赖机制抑制携带人 MM 异种移植物的小鼠的肿瘤生长[1]。 Animal Model: SCID mice with palpable RPMI8226 tumors[1] Dosage: 0.3, 3 and 9 mg/kg Administration: Intraperitoneal injection; twice weekly for 7 doses Result: Inhibited growth of established myeloma tumors in vivo and eradicates tumors in mice.
[References]
Chemical & Physical Properties
No Any Chemical & Physical Properties
Related Compounds
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.